Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1959

Sort by

Sort Order Select

Journal Articles

Poor prognosis is ZAP70’ed into focus in CLL

Adam J. Linley, Joseph R. Slupsky

Blood (2021) 137 (26): 3586–3587.

https://doi.org/10.1182/blood.2021011270

Published: 2021

Journal Articles

Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia

Blood (2020) 136 (2): 210–223.

https://doi.org/10.1182/blood.2019001417

Published: 2020

Includes: Supplemental data

Journal Articles

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia

Blood (2020) 135 (17): 1472–1483.

https://doi.org/10.1182/blood.2019003538

Published: 2020

Includes: Supplemental data

Journal Articles

FER and FES tyrosine kinase fusions in follicular T-cell lymphoma

Koen Debackere, Jo-Anne van der Krogt, Thomas Tousseyn, Julio Antonio Finalet Ferreiro, Katrien Van Roosbroeck, Lukas Marcelis, Carlos Graux, Daan Dierickx, Geneviève Ameye, Peter Vandenberghe, Lucienne Michaux, Jan Cools, Iwona Wlodarska

Blood (2020) 135 (8): 584–588.

https://doi.org/10.1182/blood.2019002401

Published: 2020

Includes: Supplemental data

Journal Articles

Trial in Progress: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Nichola Cooper, MD MRCP, Isabel Gorham, BS RN, Ann M. Lowe, MD, Robert P. Numerof, PhD, Sandy Tong, MD, David J. Kuter

Blood (2019) 134 (Supplement_1): 4800.

https://doi.org/10.1182/blood-2019-126544

Published: 2019

Journal Articles

Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice

Charles C. Chu, PhD, Jonathan J. Pinney, MS, Karl R. VanDerMeid, BS, Raquel Izumi, PhD, Veerendra Munugalavadla, PhD, Paul M. Barr, MD, Michael Rusty Elliott, PhD, Clive S Zent, MD

Blood (2019) 134 (Supplement_1): 682.

https://doi.org/10.1182/blood-2019-124901

Published: 2019

Journal Articles

Linking Microenvironmental Signals to Metabolic Switches and Drug Responses in Chronic Lymphocytic Leukemia

Zhenghao Chen, Gaspard Cretenet, Hanneke ter Burg, Gabriela Andrejeva, Jeffrey C Rathmell, Francesco Forconi, MD DM, PhD FRCPath, Gerritje J. W. van der Windt, Arnon P. Kater, Eric Eldering

Blood (2019) 134 (Supplement_1): 479.

https://doi.org/10.1182/blood-2019-123005

Published: 2019

Journal Articles

Analysis of Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients: Preliminary Results of an Open Label Phase II Trial (FIBROMET)

Paula De Melo Campos, MD, Katia B Pagnano, MD PhD, Rubia Mancuso, Francisco Breno S. Teófilo, Juan L Coelho-Silva, BSc, MSc, Fernanda I Della Via, MSc, Leandro Luiz Lopes Freitas, MD PhD, Hernandes F. Carvalho, PhD, Fernando Ferreira Costa, MD PhD, Fabiola Traina, MD PhD, Sara T Olalla Saad, PhD

Blood (2019) 134 (Supplement_1): 554.

https://doi.org/10.1182/blood-2019-130648

Published: 2019

Journal Articles

In Human Visualization of Ibrutinib-Induced CLL Compartment Shift

Marius E Mayerhoefer, Alexander Haug, Ulrich Jaeger, MD, Lukas Kazianka, MD, Verena Pichler, Sarah Pfaff, Hans-Jürgen Wester, PhD, Marcus Hacker, Philipp Bernhard Staber, MD PhD

Blood (2019) 134 (Supplement_1): 1750.

https://doi.org/10.1182/blood-2019-131469

Published: 2019

Journal Articles

Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Jennifer Woyach, MD, Amy S. Ruppert, MAS, PhD, Gabriela Perez, MS, Allison M Booth, Diane Feldman, Elie G Dib, MD, Aminah Jatoi, MD, Jennifer Le-Rademacher, PhD, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Richard Little, MD, Wei Ding, MD PhD, Brian T. Hill, MD, Richard M. Stone, MD, Sumithra J Mandrekar, PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1751.

https://doi.org/10.1182/blood-2019-127102

Published: 2019

Journal Articles

High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients

Blood (2019) 134 (Supplement_1): 1752.

https://doi.org/10.1182/blood-2019-128899

Published: 2019

Journal Articles

Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL

Jennifer Woyach, MD, Shanmugapriya Thangavadivel, PhD, David Weiss, Lai Wei, PhD, Eric McLaughlin, MS, Kerry Rogers, Seema A. Bhat, MD, Michael R. Grever, MD, Michael Keller, Matthew Dort, Gerard Lozanski, MD, Barbara Andersen, PhD, John C. Byrd, MD, Farrukh T. Awan, MD

Blood (2019) 134 (Supplement_1): 1759.

https://doi.org/10.1182/blood-2019-131099

Published: 2019

Journal Articles

Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Aneel Paulus, MD, Victoria R. Alegria, Betsy Laplant, MS, Muhamad Alhaj Moustafa, MD, Dustin Chapin, Keisha Jackson, Prachi Jani, MD, Salman Ahmed, MD, Brett Edwards, Alak Manna, PhD, Vivek Roy, MD, Taimur Sher, MD, Asher A. Chanan-Khan, MD

Blood (2019) 134 (Supplement_1): 1912.

https://doi.org/10.1182/blood-2019-128233

Published: 2019

Journal Articles

Tyrosine Kinase Inhibitors (TKIs) Targeting Syk and BTK Signaling Differentially Affect PI3K Signalosome Organization and Platelet Function

Tony Zheng, Elizabeth R Lofurno, Sarah Elgamal, Alexander R Melrose, Jiaqing Pang, Joseph J Shatzel, MD, Owen J T McCarty, PhD, Joseph Aslan, PhD

Blood (2019) 134 (Supplement_1): 2074.

https://doi.org/10.1182/blood-2019-129066

Published: 2019

Journal Articles

Activation of the Receptor Tyrosine Kinase (RET) By GDNF/GFRα1 Improves Cord Blood-Derived HSC in Vitro expansion and In Vivo engraftment

William Grey, PhD MSc, Rakhee Chauhan, PhD, Manuel Garcia-Albornoz, Hector Huerga Encabo, Neil McDonald, PhD, Dominique Bonnet, PhD

Blood (2019) 134 (Supplement_1): 1924.

https://doi.org/10.1182/blood-2019-121331

Published: 2019

Journal Articles

Updated Meta-Analysis to Evaluate the Incidence of Atrial Fibrillation and Major Bleeding in Patients with Hematologic Malignancies Treated with Ibrutinib

Sriman Swarup, MDMBBS, Anita Sultan, MD, Lukman Tijani, MD, Thura Win Htut, MBBS, MRCP, Nicholas D'Cunha, MD, Sariya Wongsaengsak, MD, Donald P. Quick, MD, Khaing Khaing Htwe, Pwint Phyu Hlaing, MD, Myat Min Han, MD, Yin Mon Myat, MD, Akshar Dash, Fred Hardwicke, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 2200.

https://doi.org/10.1182/blood-2019-123261

Published: 2019

Journal Articles

The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia

Elizabeth M. Muhowski, Amy M. Lehman, M.A.S, Sean D. Reiff, PhD, Janani Ravikrishnan, Rose Mantel, Shrilekha Misra, Michael Niesman, PhD, Kai Zhang, MD, James S. Blachly, MD, Deepa Sampath, PhD, John C. Byrd, MD, Jennifer Woyach, MD

Blood (2019) 134 (Supplement_1): 2077.

https://doi.org/10.1182/blood-2019-128871

Published: 2019

Journal Articles

A Systematic Review and Meta-Analysis of Cardio-Vascular Side Effects with Fostamatinib a Spleen Tyrosine Kinase Inhibitor

Muhammad Zain Farooq, MD MBBS, Prasanth Lingamaneni, Saira Farid, MD, Muhammad Saad Farooq, MBBS, Ishaan Vohra, MD, Asim Tameez ud din, MD, Ankit Mangla, MBBS,MD

Blood (2019) 134 (Supplement_1): 3465.

https://doi.org/10.1182/blood-2019-132151

Published: 2019

Journal Articles

Prophylactic Itacitinib (INCB039110) for the Prevention of Cytokine Release Syndrome Induced By Chimeric Antigen Receptor T-Cells (CAR-T-cells) Therapy

Eduardo Huarte, PhD, Roddy S O'Connor, PhD, Melissa Parker, Taisheng Huang, Michael C. Milone, Paul Smith

Blood (2019) 134 (Supplement_1): 1934.

https://doi.org/10.1182/blood-2019-128288

Published: 2019

Journal Articles

Fyn Specifically Regulates the Activity of Red Cell Glucose-6-Phosphate-Dehydrogenase

Blood (2019) 134 (Supplement_1): 3527.

https://doi.org/10.1182/blood-2019-125709

Published: 2019

NARROW

Poor prognosis is ZAP70’ed into focus in CLL

Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia

FER and FES tyrosine kinase fusions in follicular T-cell lymphoma

Trial in Progress: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice

Linking Microenvironmental Signals to Metabolic Switches and Drug Responses in Chronic Lymphocytic Leukemia

Analysis of Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients: Preliminary Results of an Open Label Phase II Trial (FIBROMET)

In Human Visualization of Ibrutinib-Induced CLL Compartment Shift

Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients

Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL

Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Tyrosine Kinase Inhibitors (TKIs) Targeting Syk and BTK Signaling Differentially Affect PI3K Signalosome Organization and Platelet Function

Activation of the Receptor Tyrosine Kinase (RET) By GDNF/GFRα1 Improves Cord Blood-Derived HSC in Vitro expansion and In Vivo engraftment

Updated Meta-Analysis to Evaluate the Incidence of Atrial Fibrillation and Major Bleeding in Patients with Hematologic Malignancies Treated with Ibrutinib

The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia

A Systematic Review and Meta-Analysis of Cardio-Vascular Side Effects with Fostamatinib a Spleen Tyrosine Kinase Inhibitor

Prophylactic Itacitinib (INCB039110) for the Prevention of Cytokine Release Syndrome Induced By Chimeric Antigen Receptor T-Cells (CAR-T-cells) Therapy

Fyn Specifically Regulates the Activity of Red Cell Glucose-6-Phosphate-Dehydrogenase

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only